1 publication

• Published Subscription 28 Aug 2019

  In Silico Study of Histone Deacetylase Inhibitor as Anticancer Agents

  By PARIN Sidat SIDAT, Malleshappa N. Noolvi, Vishal G. Beldar, Azmin M. Mogal

  Abstract: The clinical selective histone deacetylase inhibitor vorinostat is most commonly used for the treatment of lymphoma and solid tumor and has been preventing lives worldwide. Vorinostat is used in both treatment and prevention of lymphoma and other tumors. Based on these for current study some vorinostat derivatives with thiadiazole moiety containing derivatives have been designed for in silico study. For present work, the already selected study was against histone human …

  Published in Research & Reviews: A Journal of Drug Design & Discovery · Vol. 6, Issue 2, 2019 · pp. 6–23 Read article →